For PDE5 inhibitors, the potential cardiovascular and cerebrovascular benefits could outweigh the possible risk of Alzheimer’s disease and Lewy body dementia observed in this study. This evidence concerns the gene PDE5A and early-onset autosomal dominant Alzheimer disease.